Clinical trials
Completed Macular Edema trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
106 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 5 |
| 2004 | 5 |
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 10 |
| 2012 | 11 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 106 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Eye Institute (NEI) | 19 |
| Allergan | 9 |
| Novartis Pharmaceuticals | 5 |
| Clearside Biomedical, Inc. | 3 |
| Hoffmann-La Roche | 3 |
| Northern California Retina Vitreous Associates | 3 |
| Unity Biotechnology, Inc. | 3 |
| California Retina Consultants | 2 |
| Duke University | 2 |
| Genentech, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Edema | 106 |
| Retinal Vein Occlusion | 36 |
| Diabetic Retinopathy | 19 |
| Uveitis | 17 |
| Macular Degeneration | 15 |
| Diabetes Mellitus | 13 |
| Retinal Diseases | 12 |
| Uveitis, Intermediate | 5 |
| Choroidal Neovascularization | 4 |
| Vision Disorders | 4 |
Trials
Showing 1 to 25 of 106. Each trial links to its page on Pharma Observatory.
6 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.